Michael Thomas

23PUBLICATIONS
100CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersChemotherapyEpigenetics (incl. genome methylation and epigenomics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Oct 14, 2026
Real-World Experience With Multimodal Treatment of Resectable Stage II-III Non-Small Cell Lung Cancer: A Single Institutional Analysis.

|Oct 02, 2026
SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy.

|Jul 28, 2026
Durvalumab Consolidation After Definitive Chemoradiotherapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer: A Real-World Cohort Analysis from the German Prospective, Observational CRISP Registry (AIO-TRK-0315).

|Apr 20, 2026
Neoadjuvant Atezolizumab and Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer: Efficacy and Safety Results of an Open-Label, Single-Arm, Phase II Trial.

|Mar 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.

Benjamin Besse, Vivek Subbiah, Giuseppe Curigliano

|Mar 24, 2026
Prediction of the individual risk for the development of brain metastases in patients with non-oncogene-addicted non-small cell lung cancer: Real-world data from the German prospective CRISP registry (AIO-TRK-0315).

Fabian Acker, Katharina Wenger, Martin Reck

Pageof 4

Frequent Collaborators

6 joint publications

Albrecht Stenzinger

4 joint publications

Volker Endris

4 joint publications

Jan Budczies

3 joint publications

Thomas Muley